WuXi Biologics (Cayman) Inc. has announced that it has received the highest negligible-risk ESG rating from Morningstar Sustainalytics. This rating places the company in the top 1% globally, according to the 2025 ESG Risk Ratings conducted by the firm. This marks the fifth consecutive year that WuXi Biologics has been recognized as an Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics. The company is a participant in the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative, indicating its ongoing commitment to sustainability. WuXi Biologics has also received several other recognitions, including an MSCI AAA rating, an EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices, among others.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.